Managers / Q3 2020 · view latest →
ROBERT WOOD JOHNSON FOUNDATION
CIK 0000315157 · 50 COLLEGE ROAD EAST, PRINCETON, NJ, 08540-6614 · 6094528701
Summary
Robert Wood Johnson Foundation reported $8.3B in U.S.-listed holdings across 3 positions for Q3 2020.
The portfolio is heavily concentrated: OBDC alone accounts for 56.7% of reported value.
The book was largely unchanged from Q2 2020.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 79.9% · $6.7B
- Other · 20.1% · $1.7B
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| OBDCOWL ROCK CAPITAL CORP | ADDED | +1.39M | 3.92M | +$1.6B | $4.7B |
| ROYALTY PHARMA PLC | HELD | +0 | 3.97M | −$258M | $1.7B |
| JNJJOHNSON & JOHNSON (JNJ) | HELD | +0 | 13.00M | +$107M | $1.9B |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | OBDCOWL ROCK CAPITAL CORPhistory → | Common | 56.73% | $4.7B | 3.92M |
| 2 | JNJJOHNSON & JOHNSON (JNJ)history → | Common | 23.21% | $1.9B | 13.00M |
| 3 | ROYALTY PHARMA PLC | Common | 20.05% | $1.7B | 3.97M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $125M | 2 | Apr 29, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $124M | 2 | Jan 26, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $124M | 2 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $113M | 2 | Jul 29, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $480M | 2 | Apr 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $1.3B | 3 | Feb 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | Under review | 3 | Oct 31, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $2M | 2 | Jul 19, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $2M | 2 | May 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $2M | 2 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $2M | 4 | Nov 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $2M | 4 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $2M | 6 | May 18, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 5 | Feb 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $2.1B | 5 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $2.3B | 5 | Aug 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $2.3B | 5 | May 5, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $2.3B | 5 | Feb 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $2.1B | 5 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $2.2B | 3 | Aug 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $19.6B | 4 | May 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $9.1B | 3 | Feb 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $8.3B | 3 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $6.9B | 3 | Aug 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $3.2B | 2 | May 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.9B | 1 | Feb 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.7B | 1 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.8B | 1 | Aug 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.8B | 1 | May 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.7B | 1 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.